CD8A and neoplasm: Recently, researchers from the Italian Institute of Genomic Medicine and the Candiolo Cancer Institute, have found that the combination of gorilla adenovirus (GAd) vaccine against tumor neoantigens and PD-1 inhibitors can enhance the stemness of neoantigen-specific CD8+ T cells, increase their number, improve immunogenicity, and thus enhance anti-tumor efficacy (98).